Adjuvant interferon treatment for melanoma

Hematology/Oncology Clinics of North America

Volumn 12, Issue 4, 1998, Pages 823-833

  Agarwala, S S ^a   Kirkwood, J M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2C INTERFERON; ANTIBODY; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA; EPITOPE; GAMMA INTERFERON; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOLIPID; HLA ANTIGEN CLASS 2; ISCADUS; KEYHOLE LIMPET HEMOCYANIN; MELACINE; PHOSPHORYL LIPID A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER TOXICITY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VISCUM ALBUM;

EID: 0031660952     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70025-3     Document Type: Article

References (24)

1. S.G. Allan F.G. Hay M.A. McIntyre R.C.F. Leonard Prognosis in small cell carcinoma of the lung—relationship to human milk fat globule 2 (HMFG2) antigen and the other small cell associated antigens Br J Cancer 56 1987 485 488
2. Boon T. De Plaen E. C. Lurquin Identification of tumour rejection antigens recognized by T lymphocytes Cancer Surv 13 1992 23 37
3. A.C. Buzaid M.I. Ross C.M. Balch Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system J Clin Oncol 15 1997 1039 1051
4. N. Cascinelli Evaluation of efficacy of adjuvant rIFNa 2A in melanoma patients with regional node metastases [abstract] Proc ASCO 14 1995 A1296
5. N. Cascinelli R. Bufalino A. Morabito R. MacKie Results of adjuvant interferon study in WHO melanoma programme Lancet 343 1994 913 914
6. B.F. Cole R.D. Gelber J.M. Kirkwood A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study (E1684) J Clin Oncol 14 1996 2666 2673
7. Coulie P.G. van Pel A. Defined antigens recognized by T lymphocytes on human tumors Curr Opin Oncol 5 1993 1043 1048
8. E.T. Creagan R.J. Dalton D.L. Ahmann Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
9. A. Goldhirsch R.D. Gelber R.J. Simes Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis J Clin Oncol 7 1989 36 44
10. J.J. Grob B. Dreno M. Delaunay Long term results of an adjuvant therapy with low doses IFN-alpha2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases [abstract] Melanoma Res 7 1997 S33
11. B.E. Hillner J.M. Kirkwood M.B. Atkins Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from ECOG 1684 J Clin Oncol 15 1997 2351 2358
12. A. Isaacs J.J. Lindeman Virus interference: The interferon Proc R Soc Lond 147 1957 258 267
13. P.C. Jones L.L. Sze P.Y. Liu Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen J Natl Cancer Inst 66 1981 249 254
14. J.M. Kirkwood M.H. Strawderman M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
15. J.M. Kirkwood M.H. Strawderman M.S. Ernstoff Adjuvant therapy of high risk melanoma: The role of high-dose interferon alfa-2b Salmon S.E. Adjuvant Therapy of Cancer VIII 1997 Lippincott-Raven Philadelphia 251 257
16. S.H. Landis T. Murray S. Bolden P.A. Wingo Cancer Statistics 1998 CA-A Cancer Journal for Clinicians 48 1998 6 9
17. P.O. Livingston The case for melanoma vaccines that induce antibodies Kirkwood J.M. Molecular Diagnosis and Treatment of Melanoma 1997 Marcel Dekker New York
18. P.O. Livingston G.Y.C. Wong S. Adluri Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
19. Meyskens F.L. Jr K. Kopecky M. Samson Recombinant human interferon gamma: Adverse effects in high-risk stage I and II cutaneous malignant melanoma J Natl Cancer Inst 82 1990 1071
20. F.L. Meyskens K.J. Kopecky C.W. Taylor Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group Study J Natl Cancer Inst 87 1995 1070 1713
21. M.S. Mitchell W. Harel R.A. Kempf Active-specific immunotherapy for melanoma J Clin Oncol 8 1990 856 869
22. G.F. Murphy Cytokeratin typing of cutaneous tumors: A new immunochemical probe for cellular differentiation and malignant transformation [editorial] J Invest Dermatol 84 1985 1 2
23. S.A. Rosenberg The immunotherapy and gene therapy of cancer J Clin Oncol 10 1992 180 199
24. S.A. Rosenberg B.S. Packard P.M. Aebersold Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma N Engl J Med 319 1988 1676 1680